Skip to main content

Radiopharm Theranostics Health Care
Biotech Cancer Healthcare Medical

$0.105 -0.010 (-8.70%)

High

$0.12

Low

$0.10

Trades

57

Turnover

$206,557

Volume

1,951,148
30 June 2023 at 4:10pm
Register to track RAD and receive email alerts.
RAD Announcements on Price Chart

Latest Announcements

Headline Date
Notification of cessation of securities - RAD 30 June 2023 at 3:20pm
Notification regarding unquoted securities - RAD 30 June 2023 at 3:15pm
Pivalate educational webinar 14 June 2023 13 June 2023 at 9:05am
FDA Pre-IND meeting supports an IND application for RAD 101 29 May 2023 at 11:55am
RAD 301 receives FDA Orphan Drug Designation 9 May 2023 at 10:15am
Application for quotation of securities - RAD 28 April 2023 at 12:35pm
Quarterly Activities/Appendix 4C Cash Flow Report 27 April 2023 at 3:30pm
Agreement with TerThera to supply Terbium-161 isotope 17 April 2023 at 10:05am
Radiopharm Receives $1.56M R&D Tax Incentive 28 March 2023 at 9:50am
Radiopharm to participate in Jefferies Radiopharma Summit 28 March 2023 at 9:00am
RAD and GenesisCare to Develop Novel Radiopharmaceuticals 27 March 2023 at 9:50am
RAD to present at virtual healthcare conference 17 March 2023 at 10:30am
Notice Under Section 708A 6 March 2023 at 3:35pm
Application for quotation of securities - RAD 6 March 2023 at 3:30pm
Dr Ken Herrmann appointed to RAD Scientific Advisory Board 3 March 2023 at 10:05am
Radiopharm to acquire Pharma15 Corporation 3 March 2023 at 10:00am
Proposed issue of securities - RAD 3 March 2023 at 9:59am
Appendix 4D and Half Year Report 28 February 2023 at 5:59pm
Notification regarding unquoted securities - RAD 14 February 2023 at 5:10pm
Radiopharm Theranostics initiates process for Nasdaq listing 14 February 2023 at 9:00am
Quarterly Activities/Appendix 4C Cash Flow Report 31 January 2023 at 11:05am
Dr. Rama Abu Shmeis appointed Senior VP, CMC 11 January 2023 at 9:05am
Change in substantial holding - NT 6 January 2023 at 6:35pm
aVb6 Integrin (RAD301) IND approval for Phase 1 trial 30 December 2022 at 10:20am
RAD201 HER2 nanobody demonstrates favourable tumor targeting 13 December 2022 at 8:55am
Change in substantial holding - PH 9 December 2022 at 6:30pm
Change of Director's Interest Notice - PH 9 December 2022 at 6:20pm
Change of Director's Interest Notice - RC 9 December 2022 at 6:20pm
Change of Director's Interest Notice - IT 9 December 2022 at 6:20pm
Change of Director's Interest Notice - LA 9 December 2022 at 6:20pm
Change of Director's Interest Notice - HL 9 December 2022 at 6:15pm
Notification regarding unquoted securities - RAD 6 December 2022 at 4:35pm
Change of Director's Interest Notice - MB 2 December 2022 at 5:25pm
Change of Director's Interest Notice - IT 1 December 2022 at 3:45pm
Change of Director's Interest Notice - RC 29 November 2022 at 11:45am
Change of Director's Interest Notice - PH 29 November 2022 at 11:40am
Security Class Reinstatement to Quotation 28 November 2022 at 10:10am
Notice Under Section 708A 25 November 2022 at 5:20pm
Application for quotation of securities - RAD 25 November 2022 at 5:05pm
Top Holders Report RADO Options 25 November 2022 at 12:10pm
Appendix 2A 25 November 2022 at 11:50am
Additional data released from brain metastases imaging trial 23 November 2022 at 10:45am
Successful completion of Retail Entitlement Offer 22 November 2022 at 12:50pm
RAD agreement with ANSTO to supply key isotope lutetium-177 22 November 2022 at 8:50am
Security Class Suspension from Quotation RADO 21 November 2022 at 9:45am
Application for quotation of securities - RAD 18 November 2022 at 10:50am
Results of Annual General Meeting 16 November 2022 at 12:35pm
AGM Presentation 16 November 2022 at 10:15am
AGM ATTENDANCE 8 November 2022 at 12:15pm
Notification of Release of Shares from Escrow 8 November 2022 at 11:55am
Register to track RAD and receive email alerts.